Veto cells could make stem cell transplants safer for blood cancer patients
NCT ID NCT03622788
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-phase trial tests whether adding special immune cells called veto cells to a stem cell transplant can help donor cells grow in the patient without causing severe graft-versus-host disease (GVHD). The study includes 16 people with various blood cancers or bone marrow failure. Participants receive chemotherapy and radiation before the transplant, followed by the veto cells. The goal is to find a safe dose and see if patients are alive and engrafted 42 days later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cytokine-treated veto cells (donor immune cells)
What this could lead to
If it works, this could make stem cell transplants safer and more effective for people with blood cancers by reducing the risk of graft-versus-host disease.
What could go wrong
This is a very early, small trial (16 people) focused on finding the right dose and checking safety. It may not work as hoped, and there are risks like severe graft-versus-host disease or infection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.